More and more pharmaceutical and biotech companies are developing and launching novel, targeted therapies that offer new treatment options. It’s great news for patients - and a growing challenge for companies.
Managing and coordinating clinical supplies and then enabling access in the pre and post launch setting for these medicines is increasingly complex and expensive.
Companies need a flexible global partner focused on their specific needs. A partner who offers tailored guidance on their clinical supply chain management and the best way to enable access in unlicensed and commercial markets in line with both their and the patients' needs.
That’s when they need Clinigen.
A top 10 pharmaceutical company wanted to provide global early access to an innovative new immune-oncology medicine in high demand, responding positively to all requests across multiple tumour types, whilst providing the product free of charge (FOC) for the intended label indication.
A small pharmaceutical company with the rights to a medicine in development for Neuroblastoma was looking to quickly meet high global demand for pre-launch access, due to unmet medical need. A rapid, reliable response was also needed because of a competitive product in development.
A trial sponsor, faced with an incredibly complicated trial, needed help developing and executing a fully customised Direct-to-Patient (DtP) shipping program that enabled the trial sponsor to initiate and conduct the trial successfully.
A global pharmaceutical company developing medicines for chronic pain, cancer, asthma and autoimmune diseases needed a trusted partner to provide integrated biological sample management services across Europe and the United States.